Mobilization of progenitor cells and vessel healing after implantation of SYNERGY in acute coronary syndrome

Sakuma, Masashi; Nishino, Seiji; Nasuno, Takahisa; Kageyama, Michiya; Tokura, Michiaki; Sohma, Ryoichi; Inoue, Kazuhiro; Kanaya, Tomoaki; Obi, Syotaro; Toyoda, Shigeru; Abe, Shichiro; Attizzani, Guiherme; Pereira, Gabriel Tensol Rodrigues; Bezerra, Hiram G.; Inoue, Teruo

doi:10.1038/s41598-021-96730-9

Cited by 5 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, the same authors also reported differences in the counts of CD34+/CD133+/CD45 null and CD34+/KDR+ cells based on the stent type (with a larger response for a newer-generation ultra-thin strut DES as compared to a second-generation DES) group. Neointimal thickness and neointimal coverage rate were proportionally greater in the former [69]. In the paper by Pelliccia, 30 of the 155 patients showed in-stent restenosis at 8 months.…”

Section: Progenitor Cells Counts and Outcome After Stentingmentioning

confidence: 90%

Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist)

Gori¹

2022

Cells

View full text Add to dashboard Cite

Coronary stents are among the most common therapies worldwide. Despite significant improvements in the biocompatibility of these devices throughout the last decades, they are prone, in as many as 10–20% of cases, to short- or long-term failure. In-stent restenosis is a multifactorial process with a complex and incompletely understood pathophysiology in which inflammatory reactions are of central importance. This review provides a short overview for the clinician on the cellular types responsible for restenosis with a focus on the role of endothelial progenitor cells. The mechanisms of restenosis are described, along with the cell-based attempts made to prevent it. While the focus of this review is principally clinical, experimental evidence provides some insight into the potential implications for prevention and therapy of coronary stent restenosis.

show abstract

Section: Progenitor Cells Counts and Outcome After Stentingmentioning

confidence: 90%

Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist)

Gori¹

2022

Cells

View full text Add to dashboard Cite

show abstract

Diagnostic and therapeutic optical imaging in cardiovascular diseases

Pang,

Yuan,

Zhong

et al. 2024

iScience

View full text Add to dashboard Cite

Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells

Sohma

Sakuma

Obi

et al. 2023

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background We evaluated the efficacy of the factor Xa inhibitor rivaroxaban on the differentiation ability of vascular endothelial progenitor cells (EPCs), which play roles in vascular injury repair and atherogenesis. Antithrombotic treatment in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) is challenging, and current guidelines recommend oral anticoagulant monotherapy 1 year or more after PCI. However, biological evidence of the pharmacological effects of anticoagulants is insufficient. Methods EPC colony-forming assays were performed using peripheral blood-derived CD34-positive cells from healthy volunteers. Adhesion and tube formation of cultured EPCs were assessed in human umbilical cord-derived CD34-positive cells. Endothelial cell surface markers were assessed using flow cytometry, and Akt and endothelial nitric oxide synthase (eNOS) phosphorylation were examined using western blot analysis of EPCs. Adhesion, tube formation and endothelial cell surface marker expression was observed in EPCs transfected with small interfering RNA (siRNA) against protease-activated receptor (PAR)-2. Finally, EPC behaviors were assessed in patients with atrial fibrillation undergoing PCI in whom warfarin was changed to rivaroxaban. Results Rivaroxaban increased the number of large EPC colonies and increased the bioactivities of EPCs, including adhesion and tube formation. Rivaroxaban also increased vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, Tie-2, and E-selectin expression as well as Akt and eNOS phosphorylation. PAR-2 knockdown increased the bioactivities of EPCs and endothelial cell surface marker expression. Patients in whom the number of large colonies increased after switching to rivaroxaban showed better vascular repair. Conclusions Rivaroxaban increased the differentiation ability of EPCs, leading to potential advantages in the treatment of coronary artery disease.

show abstract

Mobilization of progenitor cells and vessel healing after implantation of SYNERGY in acute coronary syndrome

Cited by 5 publications

References 29 publications

Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist)

Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist)

Diagnostic and therapeutic optical imaging in cardiovascular diseases

Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells

Contact Info

Product

Resources

About